Drug Profile
ATL 104
Alternative Names: ATL104Latest Information Update: 21 Feb 2012
Price :
$50
*
At a glance
- Originator Alizyme
- Class
- Mechanism of Action Intercellular signalling peptide and protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Stomatitis
Most Recent Events
- 01 Jan 2010 No development reported - Phase-I/II for Stomatitis in Germany (PO)
- 01 Jan 2010 No development reported - Phase-II for Stomatitis in United Kingdom (PO)
- 31 Jul 2009 Suspended - Phase-I/II for Stomatitis in Germany (PO)